Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a registration, open-label phase 1 study of the combination of
ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple
myeloma.